Get the Stockscreener App
2.66
6.67%
-0.19
Gain Therapeutics Inc stock is traded at $2.66, with a volume of 965.49K.
It is down -6.67% in the last 24 hours and up +26.67% over the past month.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
See More
Previous Close:
$2.85
Open:
$2.83
24h Volume:
965.49K
Relative Volume:
1.12
Market Cap:
$96.40M
Revenue:
$210.70K
Net Income/Loss:
$-21.37M
P/E Ratio:
-2.4182
EPS:
-1.1
Net Cash Flow:
$-21.10M
1W Performance:
-6.01%
1M Performance:
+26.67%
6M Performance:
+46.96%
1Y Performance:
+64.20%
1-Day Range:
$2.60
$2.87
1-Week Range:
$2.60
$3.05
52-Week Range:
$1.41
$3.06
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
2.66 | 103.29M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
How Gain Therapeutics Inc. stock compares to industry benchmarksWeekly Profit Report & Expert Approved Trade Ideas - newser.com
Gain Therapeutics presents data on GT-02287 - TipRanks
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025 - The Manila Times
Gain Therapeutics (Nasdaq: GANX) Reports GT-02287 Mitochondrial, Neuronal Data - Stock Titan
Will Gain Therapeutics Inc. stock deliver strong dividend growthInsider Buying & Real-Time Volume Analysis Alerts - newser.com
Gain Therapeutics Inc. stock outlook for YEARJuly 2025 Short Interest & Risk Controlled Swing Alerts - newser.com
Is Gain Therapeutics Inc. stock ready for a breakoutWeekly Trade Recap & Weekly Breakout Watchlists - newser.com
Can machine learning forecast Gain Therapeutics Inc. recovery2025 Performance Recap & Fast Momentum Entry Tips - newser.com
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know - sharewise.com
How does Gain Therapeutics Inc (GANX) change from a tortoise to a hare? - Setenews
Is Gain Therapeutics Inc. stock undervalued vs historical averagesQuarterly Market Summary & Consistent Growth Stock Picks - newser.com
Equities Analysts Set Expectations for GANX FY2025 Earnings - Defense World
Will Gain Therapeutics Inc. stock go up soon2025 Price Targets & AI Enhanced Trading Signals - newser.com
Can Gain Therapeutics Inc. stock deliver sustainable ROEWeekly Trade Summary & AI Enhanced Trade Execution Alerts - newser.com
Why Gain Therapeutics Inc. stock remains on buy listsJuly 2025 Sector Moves & Free Safe Capital Growth Stock Tips - newser.com
Is Gain Therapeutics Inc. stock a buy before product launchesMarket Trend Review & Safe Capital Preservation Plans - newser.com
Building trade automation scripts for Gain Therapeutics Inc.Weekly Trading Summary & Verified Momentum Watchlists - newser.com
Gain Therapeutics Reports Continued Progress Amid Financial Challenges - The Globe and Mail
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Day 6 of Gains Streak for Gain Therapeutics Stock with 78% Return (vs. 37% YTD) [11/12/2025] - Trefis
[8-K] Gain Therapeutics, Inc. Reports Material Event | GANX SEC FilingForm 8-K - Stock Titan
[10-Q] Gain Therapeutics, Inc. Quarterly Earnings Report | GANX SEC FilingForm 10-Q - Stock Titan
Gain Therapeutics reports Q3 EPS (15c), consensus (15c) - TipRanks
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update - The Manila Times
Gain Therapeutics (NASDAQ: GANX) completes Phase 1b enrollment of 21; extension approved - Stock Titan
Sentiment analysis tools applied to Gain Therapeutics Inc.Weekly Market Report & Free High Return Stock Watch Alerts - newser.com
Advanced analytics toolkit walkthrough for Gain Therapeutics Inc.Quarterly Profit Summary & Weekly High Return Forecasts - newser.com
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):